Drug Trial Radar · NCT03284502
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
148
Actual
Start
May 22, 2017
Primary completion
Sep 30, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety, tolerability and pharmacokinetics of HM95573 In combination with either cobimetinib or cetuximab in patients with locally advanced or metastatic solid tumors.
Conditions
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
HM95573, cobimetinibDrug
Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib
HM95573, cetuximabDrug
Regimen: twice daily (BID), continuous dosing for HM95573
HM95573, cobimetinibDrug
Regimen: Recommended dose (RD) and schedule selected based on the data of safety, tolerability, pharmacokinetics, and anti-tumor activity tested in Stage 1
HM95573, cetuximabDrug
Regimen: Expansion dose of HM95573 selected based on the data of safety and tolerability tested in Stage 1b
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest as assessed by CTCAE v4.03Time frame: up to approximately 3 years
- Number of patients with DLTsTime frame: 28 days
- MTDs of HM95573 and cobimetinib, or HM95573 and cetuximabTime frame: End of Stage 1, an approximately 2 years
- Recommended Phase II dose (RPIID) of HM95573 and cobimetinib, or HM95573 and cetuximabTime frame: End of Stage 1, an approximately 2 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Dong-A University Hospital
Pusan, South Korea
Seoul National University Hospital
Seoul, South Korea
Yonsei University Health System Severance Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Borame Hospital
Seoul, South Korea
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.